GovChime
Notice ID: ad98bf9ecf90496fa0581049d81a9905Award NoticeAwardedArchived

6505--F18 - Flutemetamol - Flyrcado

Awarded on March 10, 2026. Full description on SAM.gov.

Awarded tounder 36C25726D0056 (source: SAM.gov award notice)• $0

Overview

Posted
March 11, 2026
Notice type
Award Notice
NAICS
325412: Pharmaceutical Preparation Manufacturing
Agency
Department of Veterans Affairs

Notice details

Office
257-NETWORK CONTRACT OFFICE 17 (36C257)
Place of performance
Delivery To: VA North Texas Health Care System
Last updated
Nov 2, 2026
First published
Last updated on SAM.gov
Award date
Mar 10, 2026
Award amount (SAM.gov award notice)
$0

Identifiers

Solicitation number
36C25726Q0205
Notice ID
ad98bf9ecf90496fa0581049d81a9905
Award number (PIID)
36C25726D0056

Description

Presolicitation Notice Notice of Intent to Award a Sole Source Procurement The Department of Veterans Affairs, Veterans Health Administration, Network Contracting Office 17, intends to award a firm-fixed priced contract to Medi-Physics, Inc. for the procurement of the following item: 0001: Flyrcado (flurpiridaz F-18) Injection, Unit of Issue: EA (mCi), Qty.: 990 The proposed sole source procurement will be made with a price that has been established on GE Healthcare s VA NAC contract 36F79725D0214. GE Healthcare has stated that orders for Flyrcado must be placed as open market orders to Medi-Physics, Inc. This notice is not to be considered a request for quotations or proposals. No contract will be awarded based on offers received in response to this notice; however, all responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency. Proposals or offers received will be used to determine if a comparable source is available and more advantageous to the government. If no affirmative written response is received within 7 days from the publication of this notice, a contract or order will be issued to Cardinal Health without any further notice. The anticipated statutory authority permitting other than full and open competition for the requirement is 41 U.S.C. 3304(a)(1), as implemented by FAR 6.302-1, only one responsible source and no other supplies or services will satisfy agency requirements.

Full description on SAM.gov

Award Overview

Award Number

36C25726D0056

Award Amount (SAM.gov award notice)

$0

Award Date

Mar 10, 2026

Awardee

Awardee UEI

CETPVZL5RQS3

Awardee CAGE Code

1WVC6

Awardee Address

ARLINGTON HEIGHTS, IL 60004, IL

Line Item Number

0001

Original Solicitation

Notice ID: ad98bf9ecf90496fa0581049d81a9905

Posted Date: Mar 11, 2026

Original Response Deadline: Not specified

Task Orders Under This IDV

Top 10 by total obligated

1
  • 36C25726N0272
    MEDI-PHYSICS, INC.
    Department of Veterans AffairsNAICS 325412
    $257.8KSigned Mar 10, 2026

More From This Vendor

Top 5 most recent

5
  • 36C24827N0039
    MEDI-PHYSICS, INC.
    Department of Veterans AffairsNAICS 325412
    $349.0KSigned Nov 6, 2026
  • 36C26327F0007
    MEDI-PHYSICS, INC.
    Department of Veterans AffairsNAICS 325412
    $69.5KSigned Nov 4, 2026
  • 36C24825N0884
    MEDI-PHYSICS, INC.
    Department of Veterans AffairsNAICS 325412
    $83.5KSigned Nov 3, 2026
  • 36C25726N0066
    MEDI-PHYSICS, INC.
    Department of Veterans AffairsNAICS 325412
    $180.7KSigned Oct 26, 2026
  • 36C25727N0013
    MEDI-PHYSICS, INC.
    Department of Veterans AffairsNAICS 325412
    $152.8KSigned Oct 26, 2026

Contacts

Contracting Officer

Primary Contact

Vance Farrell
Contract Specialist

Documents

Files (2)

  • 36C257-26-AP-0992-FY26-1695 JOFOC NCO17 Flyrcado - HCA Approved -.pdf

    172 KBAdded in Award Notice version 3Posted
    Download
  • 36C25726D0056_1.docx

    13 KBAdded in Award Notice version 3Posted
    Download

Lifecycle

  1. 3
    Version 3Award NoticeArchivedCurrent

    6505--F18 - Flutemetamol - Flyrcado

    Notice ad98bf9ecf90496fa0581049d81a9905 on SAM.gov

Other notices for this solicitation

  1. Pre-SolicitationRelated noticeJan 6, 2026

    6505--Notice of Intent to Sole Source Procurement - Flyrcado (F18 Flurpiridaz) Injection

    Notice c1c088bb4e9f42a28f940f9ea138eee8 on SAM.gov

  2. AwardedRelated noticeFeb 13, 2026

    6505--Flyrcado F18 Flurpiridaz Radiopharmaceutical Injection

    Notice fdcdf0d41f6742e59ec4713701cb32e1 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
Sources Sought Notice The Department of Veterans Affairs, Network Contracting Office (NCO) 17, is seeking sources for the following procurement: NETSPOT® Gallium Ga 68 Dotatate Injection Item (radiopharmaceutical) will be delivered to the VA North Texas Health Care System, 4500 S. Lancaster Rd., Dallas, TX 75216-7167. NCO 17 is seeking sources from firms that are capable of providing this item. Firms that can provide this item are encouraged to respond to the sources sought notice by contacting the point of contact. Capable firms must respond to the POC before the closing date and time of the notice to be considered. Capable firms must identify with their company name and are encouraged to provide a capabilities statement (if readily available) with their response. This notice is NOT a formal request for quote or proposals. No formal solicitation document exists at this time. The information in this notice is for information and planning purposes only and is not to be construed as a commitment by the government. No contract will be awarded from this notice.
-Special Notice10/30/2026
Radiopharmaceutical microspheres for William Beaumont Army Medical Center (WBAMC), Fort Bliss, TX, to support ongoing selective internal radiation therapy (SIRT) for patients presenting with unresectable metastic liver tumores secondary to colorectal cancer.
-AwardedOpen
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 newly approved drugs will be reviewed: a. Adquey - Atopic - Subclass: Topical Agents b. Armlupeg - White Blood Cell Stimulants - Subclass: Pegfilgrastims c. Beqalzi - Oncological Agents - Non-BTKI for Chronic Lymphocytic Leukemia-Small Lymphocytic Lymphoma d. Bixlenvo - Antiretrovirals - Subclass: Combinations e. Clotic - Antifungals - Subclass: NA f. Etcamah - Breast Cancer Agents - Estrogen Receptor Antagonist g. Langlara - Insulins - Subclass: Basal h. Lisraya - Targeted Immunomodulatory Biologics – NA i. Mimrylo - Hematological Agents – NA j. Nuzolvence - Antibiotics – NA k. Rasonque - Oncological Agents - Subclass: RAS Inhibitors l. Rezenopy - Alcohol Deterrants - Narcotic Antagonists The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9404. Pre-quotation teleconference is on October 14, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.
-Solicitation10/26/2026
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 newly approved drugs will be reviewed: a. Awiqli Flextouch - Insulin - Basal b. Cavhanza - Leukemia and Lymphoma Agents - BCR-ABL Tyrosine Kinase Inhibitors c. Lipfendra - Antilipidemics-1 - PCSK-9 d. Trutakna - Nephrology Agents Miscellaneous - NA The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9402. Pre-quotation teleconference is on August 12, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.
-Solicitation08/27/2026
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 drug classes/subclasses will be reviewed: a. Atopy - Topical Agents Anzupgo Eucrisa Opzelura Vtama Zoryve b. Lung Cancer - METEX14 Tabrecta Tepmetko The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9401. Pre-quotation teleconference is on August 12, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference.
-Solicitation10/01/2026

Additional Details

Solicitation Number

36C25726Q0205

Archive Date

Apr 11, 2026

Office Address

San Antonio, TX, 78240